BiomX extends IBD collaboration with Boehringer Ingelheim 04-Jul-2022 By Will Chu Microbiome firm BiomX is to continue collaborating with pharma giants Boehringer Ingelheim in a partnership that looks to identify biomarkers for inflammatory bowel disease (IBD).